This is the first study to demonstrate an important and novel role for the anti-angiogenic pathway, FKBPL-CD44, in the pathogenesis of preeclampsia, which could be utilized for the prediction, diagnosis, and treatment of preeclampsia. The gene discussed is CD44; the disease is preeclampsia.